ML 337Selective negative allosteric modulator of mGlu3 CAS# 1443118-44-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1443118-44-2 | SDF | Download SDF |
| PubChem ID | 60204017 | Appearance | Powder |
| Formula | C21H20FNO3 | M.Wt | 353.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 20 mM in ethanol | ||
| Chemical Name | [2-fluoro-4-[2-(4-methoxyphenyl)ethynyl]phenyl]-[(3R)-3-hydroxypiperidin-1-yl]methanone | ||
| SMILES | COC1=CC=C(C=C1)C#CC2=CC(=C(C=C2)C(=O)N3CCCC(C3)O)F | ||
| Standard InChIKey | QBCRLDPMQHPGIM-QGZVFWFLSA-N | ||
| Standard InChI | InChI=1S/C21H20FNO3/c1-26-18-9-6-15(7-10-18)4-5-16-8-11-19(20(22)13-16)21(25)23-12-2-3-17(24)14-23/h6-11,13,17,24H,2-3,12,14H2,1H3/t17-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective negative allosteric modulator of mGlu3 (IC50 = 593 nM). Displays no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 30 μM. Brain penetrant. |
ML 337 Dilution Calculator
ML 337 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8297 mL | 14.1487 mL | 28.2973 mL | 56.5947 mL | 70.7434 mL |
| 5 mM | 0.5659 mL | 2.8297 mL | 5.6595 mL | 11.3189 mL | 14.1487 mL |
| 10 mM | 0.283 mL | 1.4149 mL | 2.8297 mL | 5.6595 mL | 7.0743 mL |
| 50 mM | 0.0566 mL | 0.283 mL | 0.5659 mL | 1.1319 mL | 1.4149 mL |
| 100 mM | 0.0283 mL | 0.1415 mL | 0.283 mL | 0.5659 mL | 0.7074 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dehydroadynerigenin glucosyldigitaloside
Catalog No.:BCN1568
CAS No.:144223-70-1
- YYA-021
Catalog No.:BCC5346
CAS No.:144217-65-2
- 1-Acetyl-4-methylpiperazine hydrochloride
Catalog No.:BCC6615
CAS No.:144205-68-5
- Indoxacarb
Catalog No.:BCN2263
CAS No.:144171-61-9
- Ledipasvir acetone
Catalog No.:BCC4046
CAS No.:1441674-54-9
- Eprosartan Mesylate
Catalog No.:BCC4658
CAS No.:144143-96-4
- Fmoc-Glu-OAll
Catalog No.:BCC3490
CAS No.:144120-54-7
- Fmoc-Asp-OAll
Catalog No.:BCC3086
CAS No.:144120-53-6
- Tarasaponin VII
Catalog No.:BCN2684
CAS No.:144118-18-3
- Deltarasin hydrochloride
Catalog No.:BCC4270
CAS No.:1440898-82-7
- Deltarasin
Catalog No.:BCC1524
CAS No.:1440898-61-2
- Febuxostat
Catalog No.:BCC2556
CAS No.:144060-53-7
- 1-Deazaadenosine
Catalog No.:BCC6204
CAS No.:14432-09-8
- Trilepisflavan
Catalog No.:BCN6786
CAS No.:1443218-16-3
- YM 26734
Catalog No.:BCC7396
CAS No.:144337-18-8
- Nemoralisin C
Catalog No.:BCN7680
CAS No.:1443421-84-8
- CCG 203971
Catalog No.:BCC5601
CAS No.:1443437-74-8
- GSK2838232
Catalog No.:BCC6372
CAS No.:1443461-21-9
- 8-(7-Hydroxy-3,7-dimethyl-2,5-octadienyloxy)psoralen
Catalog No.:BCN1567
CAS No.:144398-34-5
- 3-Oxopomolic acid methyl ester
Catalog No.:BCN3723
CAS No.:14440-23-4
- Canophyllal
Catalog No.:BCN7441
CAS No.:14440-40-5
- 3-O-(E)-p-Coumaroylbetulin
Catalog No.:BCN6247
CAS No.:144424-80-6
- Aflavarin
Catalog No.:BCN7410
CAS No.:144429-67-4
- Goniodiol 8-acetate
Catalog No.:BCN4787
CAS No.:144429-71-0
[Correlative factors on prevalence rate of dislipidemia among 1 337 coal miners in Shanxi province].[Pubmed:28231659]
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Feb 10;38(2):163-167.
Objective: To understand the prevalence rate and correlative factors of dislipidemia among Shanxi coal miners and to provide evidence for the development of programs on dislipidemia prevention. Methods: We investigated 1 337 mine workers from a Coal Group in April 2016 and collected data related to their blood biochemistry. We then classified the types in accordance with the diagnostic criteria of " Guidelines for prevention and treatment of dyslipidemia in Chinese adults (2007)" , using chi(2) test and unconditional logistic regression model for analysis. Results: The overall prevalence rate of Dislipidemia was 59.1% (790/1 337), with males as 60.4% (708/1 173) and females as 50.0%(82/164) while males appeared higher (chi(2)=6.386, P<0.05). Among the 20-34, 35-49, 50 and above year-old groups, the rates were 68.8%, 58.7%, 49.5%, respectively. Results from the chi(2) test showed that gender, age and body mass index were the influencing factors on dislipidemia (chi(2)=7.117, P<0.01; chi(2)=37.135, P<0.01; chi(2)=7.009, P<0.05), while logistic regression analysis showed that sex, age, body mass index level, systolic blood pressure were significantly associated with dislipidemia (P<0.05). Male miners appeared 1.501 times (OR=1.501, 95%CI: 1.895-2.516) higher than female miners in suffering from the risk of dyslipidemia. In different age groups, risks of dyslipidemia in the 35-49, 20-34 year-old groups were 1.672 (OR=1.672, 95%CI: 1.501-2.392) and 2.369 times (OR= 2.369, 95% CI: 1.275-3.469) higher than the 50 year-old. Group that with high BMI, the risk of dyslipidemia was 1.443 times (OR=1.443, 95%CI: 1.139-1.828) higher than the normal BMI group. Group with abnormal systolic pressure was 1.829 times (OR=1.829, 95%CI: 1.152-2.906) higher than normal systolic pressure group. However, diastolic blood pressure, blood sugar, uric acid, and electrocardiogram findings did not seem to show statistically significant meanings on dislipidemia. Conclusion: Among the coal mine workers, those who were males, aged from 20 to 34, having high blood pressure (systolic blood pressure abnormalities) or with high BMI (>/=24.0 kg/m(2)) need to be taken special attention on care and prevention of dislipidemia.
[Retrospective analysis on 337 cases of Henoch-Schonlein purpura].[Pubmed:28216501]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Jan 28;42(1):72-77.
OBJECTIVE: To determine differences in incidence, causes, clinical manifestation,prognosis between children and adults in patients with Henoch-Schonlein purpura (HSP). Methods: We retrospectively analyzed clinical data of 337 patients who hospitalized in the Department of Dermatology, Peace Hospital affiliated to Changzhi Medical College from Feb. 2013 to Jan. 2016. All patients were divided into two groups by age: a child group (patients were less than 14 years old) and an adult group (patients were more than or equal to 14 years old). The incidence, inducement, and recovery rates were compared between 2 groups. Results: There were 195 (57.86%) children and 142 (42.14%) adults in all subjects, and 143 (42.43%) were less than 10 years old. The incidence of HSP in children in autumn and winter was higher than that in adults (P<0.05). Children with upper respiratory infection outnumbered adults (P<0.01). Logistic analysis results showed that age more than 14 years old, gastrointestinal symptoms, skin purpura relapsed more than 3 times, and overexpression of anti-streptolysin O(ASO) were high risk factors for the HSP kidney damage (P<0.05). Increased white blood cell count, high percentage of neutrophil, and increased platelet count were independent risk factors for gastrointestinal symptoms (P<0.05). The curative rates for children were higher than those of adults (P<0.05) and curative rates of patients without kidney damage were higher than those in patients with kidney damage (P<0.05). Conclusion: HSP mainly occurs in children, especially in those under 10 years old. Compared with adult patients, children with HSP are easy to be induced by upper respiratory tract infection, with relatively mild renal damage and better prognosis.
Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).[Pubmed:23718281]
J Med Chem. 2013 Jun 27;56(12):5208-12.
A multidimensional, iterative parallel synthesis effort identified a series of highly selective mGlu3 NAMs with submicromolar potency and good CNS penetration. Of these, ML337 resulted (mGlu3 IC50 = 593 nM, mGlu2 IC50 >30 muM) with B:P ratios of 0.92 (mouse) to 0.3 (rat). DMPK profiling and shallow SAR led to the incorporation of deuterium atoms to address a metabolic soft spot, which subsequently lowered both in vitro and in vivo clearance by >50%.
